Compare GSK plc (GSK) vs iShares Gold Trust (IAU) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

IAU shares are trading at $74.92, down 1.77% amid broader gold market weakness. The technical picture shows bearish momentum with selling pressure across moving averages, while oscillators remain neutral. Recent economic data including stronger retail sales and manufacturing activity have pressured gold prices, offsetting earlier inflation relief. The stock faces resistance at $77 with support at $76.

The outlook remains cautious as Federal Reserve policy uncertainty and Treasury yield movements continue to drive gold price volatility. While central bank accumulation provides long-term support, near-term headwinds from economic data and dollar strength suggest continued pressure. Investors should monitor Fed communications and inflation trends for directional catalysts.